A citation-based method for searching scientific literature

Almira Auyez, A Emre Sayan, Marina Kriajevska, Eugene Tulchinsky. Cancers (Basel) 2021
Times Cited: 6







List of co-cited articles
83 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer.
Zhenfeng Zhang, Jae Cheol Lee, Luping Lin, Victor Olivas, Valerie Au, Thomas LaFramboise, Mohamed Abdel-Rahman, Xiaoqi Wang, Alan D Levine, Jin Kyung Rho,[...]. Nat Genet 2012
859
66

AXL-GAS6 expression can predict for adverse prognosis in non-small cell lung cancer with brain metastases.
Xiaoliang Wu, Wenjuan Ma, Qianghua Zhou, Haijuan Yan, Zuan-Fu Lim, Mayan Huang, Chuangzhong Deng, Xingsu Yu, Huifang Su, Satoshi Komo,[...]. J Cancer Res Clin Oncol 2017
28
50

Therapeutic Targeting of the Gas6/Axl Signaling Pathway in Cancer.
Mai Tanaka, Dietmar W Siemann. Int J Mol Sci 2021
9
50

Regulation of Axl receptor tyrosine kinase expression by miR-34a and miR-199a/b in solid cancer.
G Mudduluru, P Ceppi, R Kumarswamy, G V Scagliotti, M Papotti, H Allgayer. Oncogene 2011
194
50

R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer.
Sacha J Holland, Alison Pan, Christian Franci, Yuanming Hu, Betty Chang, Weiqun Li, Matt Duan, Allan Torneros, Jiaxin Yu, Thilo J Heckrodt,[...]. Cancer Res 2010
353
50


TAM receptors are pleiotropic inhibitors of the innate immune response.
Carla V Rothlin, Sourav Ghosh, Elina I Zuniga, Michael B A Oldstone, Greg Lemke. Cell 2007
702
50

Axl mediates acquired resistance of head and neck cancer cells to the epidermal growth factor receptor inhibitor erlotinib.
Keith M Giles, Felicity C Kalinowski, Patrick A Candy, Michael R Epis, Priscilla M Zhang, Andrew D Redfern, Lisa M Stuart, Gregory J Goodall, Peter J Leedman. Mol Cancer Ther 2013
116
50

axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase.
J P O'Bryan, R A Frye, P C Cogswell, A Neubauer, B Kitch, C Prokop, R Espinosa, M M Le Beau, H S Earp, E T Liu. Mol Cell Biol 1991
623
50

Association of AXL and PD-L1 Expression with Clinical Outcomes in Patients with Advanced Renal Cell Carcinoma Treated with PD-1 Blockade.
Stéphane Terry, Cécile Dalban, Nathalie Rioux-Leclercq, Julien Adam, Maxime Meylan, Stéphanie Buart, Antoine Bougoüin, Alexandra Lespagnol, Frédéric Dugay, Irelka Colina Moreno,[...]. Clin Cancer Res 2021
15
50

Design, Synthesis and Biological Evaluation of a Series of Novel Axl Kinase Inhibitors.
Alexis Mollard, Steven L Warner, Lee T Call, Mark L Wade, Jared J Bearss, Anupam Verma, Sunil Sharma, Hariprasad Vankayalapati, David J Bearss. ACS Med Chem Lett 2011
57
50

AXL Inhibitors in Cancer: A Medicinal Chemistry Perspective.
Samuel H Myers, Valerie G Brunton, Asier Unciti-Broceta. J Med Chem 2016
119
50

Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma.
Isabel Ben-Batalla, Alexander Schultze, Mark Wroblewski, Robert Erdmann, Michael Heuser, Jonas S Waizenegger, Kristoffer Riecken, Mascha Binder, Denis Schewe, Stefanie Sawall,[...]. Blood 2013
152
50

Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth.
F Michael Yakes, Jason Chen, Jenny Tan, Kyoko Yamaguchi, Yongchang Shi, Peiwen Yu, Fawn Qian, Felix Chu, Frauke Bentzien, Belinda Cancilla,[...]. Mol Cancer Ther 2011
822
50

The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells.
Magdalena Paolino, Axel Choidas, Stephanie Wallner, Blanka Pranjic, Iris Uribesalgo, Stefanie Loeser, Amanda M Jamieson, Wallace Y Langdon, Fumiyo Ikeda, Juan Pablo Fededa,[...]. Nature 2014
287
50

An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance.
Lauren Averett Byers, Lixia Diao, Jing Wang, Pierre Saintigny, Luc Girard, Michael Peyton, Li Shen, Youhong Fan, Uma Giri, Praveen K Tumula,[...]. Clin Cancer Res 2013
663
50



Higher expression of receptor tyrosine kinase Axl, and differential expression of its ligand, Gas6, predict poor survival in lung adenocarcinoma patients.
Masashi Ishikawa, Makoto Sonobe, Ei Nakayama, Masashi Kobayashi, Ryutaro Kikuchi, Jiro Kitamura, Naoto Imamura, Hiroshi Date. Ann Surg Oncol 2013
60
33

Gas6 derived from cancer-associated fibroblasts promotes migration of Axl-expressing lung cancer cells during chemotherapy.
Ryu Kanzaki, Hisamichi Naito, Kazuyoshi Kise, Kazuhiro Takara, Daisuke Eino, Masato Minami, Yasushi Shintani, Soichiro Funaki, Tomohiro Kawamura, Toru Kimura,[...]. Sci Rep 2017
29
33

Tumor tissue and plasma levels of AXL and GAS6 before and after tyrosine kinase inhibitor treatment in EGFR-mutated non-small cell lung cancer.
Yoshikane Nonagase, Masayuki Takeda, Koichi Azuma, Hidetoshi Hayashi, Koji Haratani, Kaoru Tanaka, Kimio Yonesaka, Hidenobu Ishii, Tomoaki Hoshino, Kazuhiko Nakagawa. Thorac Cancer 2019
6
33


MERTK Mediates Intrinsic and Adaptive Resistance to AXL-targeting Agents.
Nellie K McDaniel, Christopher T Cummings, Mari Iida, Justus Hülse, Hannah E Pearson, Eleana Vasileiadi, Rebecca E Parker, Rachel A Orbuch, Olivia J Ondracek, Noah B Welke,[...]. Mol Cancer Ther 2018
26
33

Vitamin K-dependent Gas6 activates ERK kinase and stimulates growth of cardiac fibroblasts.
Jonas Stenhoff, Björn Dahlbäck, Sassan Hafizi. Biochem Biophys Res Commun 2004
95
33

Targeting MERTK and AXL in EGFR Mutant Non-Small Cell Lung Cancer.
Dan Yan, H Shelton Earp, Deborah DeRyckere, Douglas K Graham. Cancers (Basel) 2021
5
40

An anti-Axl monoclonal antibody attenuates xenograft tumor growth and enhances the effect of multiple anticancer therapies.
X Ye, Y Li, S Stawicki, S Couto, J Eastham-Anderson, D Kallop, R Weimer, Y Wu, L Pei. Oncogene 2010
159
33

Malignant cells fuel tumor growth by educating infiltrating leukocytes to produce the mitogen Gas6.
Sonja Loges, Thomas Schmidt, Marc Tjwa, Katie van Geyte, Dirk Lievens, Esther Lutgens, Davy Vanhoutte, Delphine Borgel, Stephane Plaisance, Marc Hoylaerts,[...]. Blood 2010
120
33

The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia.
Katherine A Minson, Catherine C Smith, Deborah DeRyckere, Clara Libbrecht, Alisa B Lee-Sherick, Madeline G Huey, Elisabeth A Lasater, Gregory D Kirkpatrick, Michael A Stashko, Weihe Zhang,[...]. JCI Insight 2016
36
33

Targeting AXL in NSCLC.
Aubhishek Zaman, Trever G Bivona. Lung Cancer (Auckl) 2021
3
66

AXL mediates resistance to cetuximab therapy.
Toni M Brand, Mari Iida, Andrew P Stein, Kelsey L Corrigan, Cara M Braverman, Neha Luthar, Mahmoud Toulany, Parkash S Gill, Ravi Salgia, Randall J Kimple,[...]. Cancer Res 2014
131
33

Activation of the Receptor Tyrosine Kinase AXL Regulates the Immune Microenvironment in Glioblastoma.
Hirokazu Sadahiro, Kyung-Don Kang, Justin T Gibson, Mutsuko Minata, Hai Yu, Junfeng Shi, Rishi Chhipa, Zhihong Chen, Songjian Lu, Yannick Simoni,[...]. Cancer Res 2018
79
33

The receptor tyrosine kinase ARK mediates cell aggregation by homophilic binding.
P Bellosta, M Costa, D A Lin, C Basilico. Mol Cell Biol 1995
159
33

Structural basis for Gas6-Axl signalling.
Takako Sasaki, Pjotr G Knyazev, Naomi J Clout, Yuri Cheburkin, Walter Göhring, Axel Ullrich, Rupert Timpl, Erhard Hohenester. EMBO J 2006
177
33

Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL.
Li Liu, James Greger, Hong Shi, Yuan Liu, Joel Greshock, Roland Annan, Wendy Halsey, Ganesh M Sathe, Anne-Marie Martin, Tona M Gilmer. Cancer Res 2009
346
33


TAM Receptor Inhibition-Implications for Cancer and the Immune System.
Pia Aehnlich, Richard Morgan Powell, Marlies J W Peeters, Anne Rahbech, Per Thor Straten. Cancers (Basel) 2021
13
33

AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas.
Moshe Elkabets, Evangelos Pazarentzos, Dejan Juric, Qing Sheng, Raphael A Pelossof, Samuel Brook, Ana Oaknin Benzaken, Jordi Rodon, Natasha Morse, Jenny Jiacheng Yan,[...]. Cancer Cell 2015
215
33

Stromal Gas6 promotes the progression of premalignant mammary cells.
Angelica M Gomes, Emily C Carron, Kylie L Mills, Alexa M Dow, Zane Gray, Christopher R Fecca, Meredith A Lakey, Peter Carmeliet, Frances Kittrell, Daniel Medina,[...]. Oncogene 2019
21
33

Soluble AXL is a novel blood marker for early detection of pancreatic ductal adenocarcinoma and differential diagnosis from chronic pancreatitis.
Neus Martínez-Bosch, Helena Cristóbal, Mar Iglesias, Meritxell Gironella, Luis Barranco, Laura Visa, Domenico Calafato, Silvia Jiménez-Parrado, Julie Earl, Alfredo Carrato,[...]. EBioMedicine 2022
5
40

An engineered Axl 'decoy receptor' effectively silences the Gas6-Axl signaling axis.
Mihalis S Kariolis, Yu Rebecca Miao, Douglas S Jones, Shiven Kapur, Irimpan I Mathews, Amato J Giaccia, Jennifer R Cochran. Nat Chem Biol 2014
92
33

Loss of the receptor tyrosine kinase Axl leads to enhanced inflammation in the CNS and delayed removal of myelin debris during experimental autoimmune encephalomyelitis.
Jason G Weinger, Celia F Brosnan, Olivier Loudig, Michael F Goldberg, Fernando Macian, Heather A Arnett, Anne L Prieto, Vladislav Tsiperson, Bridget Shafit-Zagardo. J Neuroinflammation 2011
78
33

Requirement of Gamma-Carboxyglutamic Acid Modification and Phosphatidylserine Binding for the Activation of Tyro3, Axl, and Mertk Receptors by Growth Arrest-Specific 6.
Ke Geng, Sushil Kumar, Stanley G Kimani, Vladyslav Kholodovych, Canan Kasikara, Kensaku Mizuno, Oleta Sandiford, Pranela Rameshwar, Sergei V Kotenko, Raymond B Birge. Front Immunol 2017
39
33

Reprogramming the immunological microenvironment through radiation and targeting Axl.
Todd A Aguilera, Marjan Rafat, Laura Castellini, Hussein Shehade, Mihalis S Kariolis, Angela Bik-Yu Hui, Henning Stehr, Rie von Eyben, Dadi Jiang, Lesley G Ellies,[...]. Nat Commun 2016
100
33

A Potent and Selective Dual Inhibitor of AXL and MERTK Possesses Both Immunomodulatory and Tumor-Targeted Activity.
Jonathan Rios-Doria, Margaret Favata, Kerri Lasky, Patricia Feldman, Yvonne Lo, Gengjie Yang, Christina Stevens, Xiaoming Wen, Sarita Sehra, Kamna Katiyar,[...]. Front Oncol 2020
11
33

UNC2025, a potent and orally bioavailable MER/FLT3 dual inhibitor.
Weihe Zhang, Deborah DeRyckere, Debra Hunter, Jing Liu, Michael A Stashko, Katherine A Minson, Christopher T Cummings, Minjung Lee, Trevor G Glaros, Dianne L Newton,[...]. J Med Chem 2014
91
33

Axl-EGFR receptor tyrosine kinase hetero-interaction provides EGFR with access to pro-invasive signalling in cancer cells.
M Vouri, D R Croucher, S P Kennedy, Q An, G J Pilkington, S Hafizi. Oncogenesis 2016
51
33

Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival.
Christine Gjerdrum, Crina Tiron, Torill Høiby, Ingunn Stefansson, Hallvard Haugen, Tone Sandal, Karin Collett, Shan Li, Emmet McCormack, Bjørn Tore Gjertsen,[...]. Proc Natl Acad Sci U S A 2010
406
33


Antitumor immune effects of preoperative sitravatinib and nivolumab in oral cavity cancer: SNOW window-of-opportunity study.
Marc Oliva, Douglas Chepeha, Daniel V Araujo, J Javier Diaz-Mejia, Peter Olson, Amy Prawira, Anna Spreafico, Scott V Bratman, Tina Shek, John de Almeida,[...]. J Immunother Cancer 2021
9
33

Axl and Mertk Receptors Cooperate to Promote Breast Cancer Progression by Combined Oncogenic Signaling and Evasion of Host Antitumor Immunity.
Viralkumar Davra, Sushil Kumar, Ke Geng, David Calianese, Dhriti Mehta, Varsha Gadiyar, Canan Kasikara, Kevin C Lahey, Yun-Juan Chang, Michael Wichroski,[...]. Cancer Res 2021
21
33


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.